Abstract
Although medulloblastoma and neuroblastoma share many common biological, histological and immunological features, the frequency of N-myc amplification differs markedly between the two tumours. In this study, Southern blot analysis revealed that the N-myc gene was not amplified in any of the nine medulloblastoma samples analysed. In contrast, over-expression of the gene was found in six of 11 samples as determined by immunocytochemistry and/or Western blot analysis, using an antiserum raised against a synthetic peptide representing a sequence unique to the N-myc gene product. The specificity of this reagent was demonstrated by studies on a variety of cell lines expressing N-myc and/or c-myc oncoproteins. Of the 12 medulloblastoma samples collected over a two-year period and analysed in the course of this project, a trend towards longer disease-free survival was noted in the patients having low levels of the N-myc protein in their tumour.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garson, J., Pemberton, L., Sheppard, P. et al. N-myc gene expression and oncoprotein characterisation in medulloblastoma. Br J Cancer 59, 889–894 (1989). https://doi.org/10.1038/bjc.1989.188
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.188
- Springer Nature Limited
This article is cited by
-
Cytogenetic characterization of the malignant primitive neuroectodermal SK-PN-DW tumor cell line
BMC Cancer (2019)
-
BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis
Nature Communications (2016)
-
Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma
Journal of Neuro-Oncology (2011)
-
c- and N-myc Regulate Neural Precursor Cell Fate, Cell Cycle, and Metabolism to Direct Cerebellar Development
The Cerebellum (2010)
-
Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression
Oncogene (2009)